TickerTalks
Browse all tickers →
TickerTalks›$AARD
AAAARD

Aardvark Therapeutics, Inc. Common Stock

$AARD·$109M·Biotechnology·Healthcare
$4.81+2.1%YTD-64.6%1Y-71.5%
Price updated 10m ago·X counts updated 5d ago
AAAARD
$AARDAardvark Therapeutics, Inc. Common Stock
$4.81+2.12%2 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $AARD on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

2X posts · last 7 days
Sep 21Oct 4

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $AARD — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-10-02

Falling on heavy selling — points lower unless it turns around.

Clinical-stage biotech at $5.27 after -60% YTD, -64% trailing-12m and an Oct 13 class-action lead-plaintiff deadline.

Aardvark Therapeutics develops small-molecule immuno-metabolic therapies in clinical trials, so valuation is pre-revenue biotech with clinical-readout dependency and ongoing cash burn.

  • Pre-revenue through Q1 FY26 (zero revenue, operating losses $0.66-0.99 per share quarterly)
  • TTM: -2.4x earnings (negative), -62% ROE, FCF yield -37%, debt-to-equity 0.004
  • 2026 estimate: $300K revenue, -$3.15 EPS; 2027 $1.03M revenue, -$2.56 EPS — modeling continued losses with minimal revenue
  • YTD -60%, trailing-12m -64% at $5.27 against a $111M market cap
  • Aug 14 Annual Meeting: 54.79% quorum; stockholders voted on three proposals
  • Multiple class-action investigations open: Pomerantz filed; SBS Law alerting investors; SueWallSt urging investors; Oct 13 2026 lead-plaintiff deadline

The equity is a clinical-stage biotech in a drawdown with multiple class-action investigations converging — the operating thesis depends on pipeline readouts, while the market-side thesis depends on legal-exposure clarity.

What to watch: Oct 13 class-action lead-plaintiff deadline and Nov 12 Q3 earnings for cash-runway commentary — whether the litigation consolidates and whether the pipeline-readout timeline is articulated.

On the calendar: 2026-11-12 Q3 earnings

Read the AI verdict on $AARD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing gut-targeted small molecules for metabolic disorders; lead drug ARD-101 is in Phase III for hyperphagia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $AARD.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $AARD

Neutral — Clinical-stage biotech developing gut-targeted small molecules for metabolic disorders; lead drug ARD-101 is in Phase III for hyperphagia.

Top industry ETF

$IBBiShares Biotechnology ETF
+18.2%YTD
+31.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-85.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-37.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-61.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.66$-0.87+24.5%
Q1 2026May 7, 2026$-0.99$-0.88-12.9%
Q4 2025Mar 23, 2026$-0.81$-0.83+2.1%
Q3 2025Nov 13, 2025$-0.75$-0.80+6.1%
Next earningsThu, Nov 12·consensus EPS $-0.74

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.99$-18.9M
Q4 FY25$0———$-0.81$-14.4M
Q3 FY25$0———$-0.75$-18.5M
Q2 FY25$0———$-0.66$-9.9M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$300K$300K – $300K-$3.15-$3.80 – -$2.469
FY27$1.0M$1.0M – $1.0M-$2.56-$3.62 – -$1.846
FY28$6.6M$6.6M – $6.6M-$2.47-$4.13 – -$1.107
FY29$104.4M$104.4M – $104.4M-$1.49-$1.49 – -$1.493
FY30$257.0M$257.0M – $257.0M$0.86$0.86 – $0.865

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-21.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-34.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 10.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.815-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 11Nelson SunSee Remarks62.0K sh$321KSellSep 10Nelson SunSee Remarks14.8K sh$74K
+ 5 other (5 awards) in window

See when $AARD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsOct 83
8-KOfficer or director changeOct 88-K — Item 5.02: Officer or director change · Item 8.01: Other event
8-KShareholder voteAug 178-K — Item 5.07: Shareholder vote
AI summary

Aardvark Therapeutics, Inc. held its 2026 Annual Meeting on August 14, 2026, with 11,992,479 of 21,884,158 outstanding shares represented (54.79% quorum). Stockholders voted on three proposals as described in the proxy statement filed July 10, 2026. No specific vote results or proposal details were captured in the excerpt. Routine annual meeting disclosure; vote outcomes would indicate any contested director elections or say-on-pay concerns.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change
AI summary

Aardvark Therapeutics entered into a retention bonus agreement with CFO/COO Nelson Sun on June 10, 2026, committing to pay a total of $346,500: a $198,000 guaranteed annual bonus for 2026 and a $148,500 retention bonus, both payable on January 1, 2027 subject to continued employment. Termination without cause or resignation for good reason before that date triggers a pro-rated payout. Given the FDA clinical hold placed on ARD-101 (see separate filing), the retention package likely reflects the company's effort to stabilize leadership during a critical regulatory challenge.

+ 8 other (2 10-Qs · 2 earnings 8-Ks · 1 ARS · 1 proxy) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARDglobenewswire.com·19h agoAARD DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARDnewsfilecorp.com·1d agoAardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuitprnewswire.com·1d agoAARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallStprnewswire.com·1d agoPomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARDprnewswire.com·1d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$KOD$MRNA$IOVA$ARCT$IBRX$VKTX$NWBO$QURE
Voices on X · last 7 days

No standout posts about $AARD on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport